Biogen Idec (NASDAQ: BIIB) will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, April 26 – May 3, 2014. The scope and rigor of the data reflects Biogen Idec’s leadership in advancing neurological research and enhancing patient outcomes in multiple sclerosis (MS) and other diseases. )--Biogen Idec (NASDAQ: BIIB) will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, April 26 – May 3, 2014. The scope and rigor of the data reflects Biogen Idec’s leadership in advancing neurological research and enhancing patient outcomes in multiple sclerosis (MS) and other diseases.